Kymera Therapeutics, LLC, a Cambridge, MA-based biotechnology company, raised $30M in Series A financing.
The round was led by Atlas Venture, which co-founded, seeded, and incubated the company, along with Lilly Ventures and Amgen Ventures.
The company intends to use the funds to advance a transformational new therapeutic modality and discover new medicines for patients with previously untreatable diseases.
Led by Nello Mainolfi, Ph.D., co-founder and chief technology officer, and Laurent Audoly, Ph.D., president and CEO, Kymera Therapeutics is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. The company’s proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools.
Kymera is currently pursuing a focused number of programs in oncology, immuno-oncology, autoimmune and inflammatory diseases, and expects to engage in strategic partnerships with biopharmaceutical companies in these and other therapeutic areas.
The company plans to nominate its first development candidate next year.
Scientific advisors include:
– David Spiegel, M.D., Ph.D., Professor of Chemistry, Yale University
– Steven A. Carr, Ph.D., Senior Director of Proteomics, Broad Institute
– Michele Pagano, M.D., Chair, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine and Investigator, Howard Hughes Medical Institute
– Ning Zheng, Ph.D., Professor of Pharmacology, University of Washington and Investigator, Howard Hughes Medical Institute
The Board of Directors includes Dr. Audoly, president and CEO; Dr. Booth, chairman; and Dr. Steve Hall, general partner at Lilly Ventures.